API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
EU WC
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
Antimalarial therapy proguanil and rheumatoid arthritis medication sulfasalazine, showed they could safety inhibit the replication of the SARS-CoV-2 coronavirus behind COVID-19 in both monkey and human cell lines, according to a new study published in Science Advances.
Lead Product(s): Proguanil,Sulfasalazine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2021